Market news

Relmada Therapeutics (RLMD) shares were up nearly 11% in afternoon trading on Friday after the compa

CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference being held in Boston, MA, from September 8 - 10, 2026. Wells Fargo 21st Annual Healthcare Conference DetailsFormat: One-o

Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Relmada Therapeutics (RLMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Detailed price information for Relmada Therapeutics Inc (RLMD-Q) from The Globe and Mail including charting and trades.

Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.

Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Detailed price information for Relmada Therapeutics Inc (RLMD-Q) from The Globe and Mail including charting and trades.

Detailed price information for Delcath Systems Inc (DCTH-Q) from The Globe and Mail including charting and trades.

Motley Fool Press Release.

Detailed price information for Relmada Therapeutics Inc (RLMD-Q) from The Globe and Mail including charting and trades.

Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company's long-term growth and value creation. CORAL GABLES, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Bipin Dalmia, PhD, MBA, as Chie

CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2026, and recent business progress. Conference Call and Webcast Information: Date: Th

Detailed price information for Relmada Therapeutics Inc (RLMD-Q) from The Globe and Mail including charting and trades.